CD38 and myeloid sarcoma: CD38+ plasmablasts were observed more frequently near MS compared to stroke microglia nodules (CD20: MS: 5 of 106 nodules, per donor 5.2% ± 10.4%, stroke: 0 out of 83 nodules, 0% ± 0% per donor; CD138: MS: 13 of 162 nodules, per donor 6.7% ± 10.7%, stroke: 0 of 78 nodules, per donor 0% ± 0%; CD38: MS: 90 of 202 nodules, per donor 34.6% ± 24.5%, stroke: 1 of 65 nodules, per donor 0.4% ± 0.9%, p = 6.7e−3, Fig. 3a–f).